negative predictive value is 1 .0. The results are available within five days, compared with 21-28 days for completion of soft-agar assays; fewer cells are required; and the process is semiautomated.
AddItIonal Keyphrases: DNA synthesis #{149} bioassay compared radicassay
Actively proliferating cells are the targets of most chemotherapeutic agents; thus, the loss of a fraction of proliferative cells because of drug treatment should reflect the therapeutic efficacy of such a drug. DNA synthesis being one of the prerequisites for cell proliferation, an effective drug treatment is expected to manifest as a decrease in DNA synthesis. This is supported by marked suppression of DNA synthesis in sensitive animal tumors after effective chemotherapy delivered in vivo (1, 2) . In the clinical setting, sensitive human tumors also exhibit prolonged suppression of DNA synthesis after radiation or chemotherapy (3) . Therefore, the suppression of DNA synthesis after exposure to the appropriate drug in vitro may predict the biological event in vivo. (4) . After incubating the cell-drug mixture for 1 h in a 37 #{176}C incubator, we added 1 mL of HBSS, then centrifuged at 300 X g for 5 mm. The cell pellet was then resuspended in 1 mL of enriched medium: to every 78 mL of RPM1 1640, we added 20 mL of fetal calf serum, 10 000 units of penicillin, 10 000 g of streptomycin, and 1 mL of glutamine (200 mmolfL The % DNA synthesis of control is plotted against log drug concentration on semi-log graph paper.
Materials and Methods

Patients
Tumor-cell dose curve and daily growth curve. To determine the cell density for optimal growth, we plated in triplicate a series of known numbers of cells in 0.2-mL volume. These were cultured for five days, pulsed, and harvested as described above. We also obtained daily growth curves for some tumors by pulsing and harvesting the cultures daily up to seven days.
Tumor-cell morphology. Cytocentrifuge preparations were made from cell suspensions before and after culture. These were stained by the Papanicolaou or Wright-Giemsa method (5, 6). For multiple myeloma and non-Hodgkin's lymphoma, the monoclonality of cytoplasmic or surface immunoglobulin was assessed by direct immunofluorescent techniques (7).
Results
Cell morphology.
The cell population is monitored morphologically before and after culture. Generally, most of the cells are confirmed as tumor cells (Figure 1 ). Any cultures overgrown by mesothelial cells are discarded from the study (here, one out of 25).
Tumor-cell
dose and daily growth curve. Typical tumor-cell dose curves of two cases of transitional cell carcinoma of the bladder are illustrated in Figure 2 (left). For 2.5 X 10 to 5 X 105 cells/mL the amount of DNA synthesized is proportional to the number of cells plated. However, the amount of DNA synthesized levels off when the number of cells increases further (1 X 106 cells/mL). Similar dose curves are observed with other carcinomas studied. Thus, for these tumors, 5 X 105 cells/mL appears to be the optimal density for cell growth. Non-Hodgkin's lymphoma produces a somewhat different dose curve (Figure 2, right) , within the dose range of 1 X 106 to 4 X 10 cells/mL; DNA synthesis does not seem to reach a plateau. A similar dose curve is observed for multiple myeloma except the range of cell numbers studied was 2.5 X i0 to 1 X 106 cells/mL. Thus, we used a cell concentration of 2 X 106 per milliliter for non-Hodgkin's lymphoma and 5 X io per milliliter for multiple myeloma in these drug-sensitivity studies. Although the cell dose curves for the same types of tumor are similar to one another, we noted a wide range of [3H]thymidmne uptake among different patients having the same type of tumor. Studies of daily [3H]thymidmne uptake revealed that the peak cell growth occurs around days four and five after culture (Figure 3) . Figure 4 depicts the reproducibility of the assay. Using biopsies obtained from the same patient on two different occasions, we studied the cells' sensitivity to adriamycin, repeating the assay four times (two on the days of biopsies and the other two with the cryopreserved cells of the biopsies). Invariably, the tumor was resistant to adriamycmn at all drug doses investigated.
Reproducibility of the assay.
Success rate of culturing the tumors. The culture is considered successful when the mean DNA synthesis of the (triplicate) control specimen, in terms of [3Hjthymidine uptake, exceeds 300 cpm or a tumor-cell dose curve is demonstrable. Of 25 tumors cultured, 19 tumors met these criteria (Table 2) . Thus, the overall success rate of culture was 76%.
Predicting the in vivo response from in vitro drug sensitivity. A good drug dose-response curve is usually observed when the tumor growth is successful, especially if the tumor is sensitive to the drug. Representative drug sensitivity of various tumors is illustrated in Figure 5 . To determine drug sensitivity in vitro, we use the value for the DNA synthesis of the cells treated with the median drug dose (corresponding I 2 E to 10% of the concentration achievable in plasma. Results greater than 60% and less than 40% of control DNA synthesis at this drug dose are defined as drug resistant and drug sensitive, respectively; in the range of 40% to 60% of the control DNA synthesis, the drug is considered to have a marginal effect. Using these criteria, we obtained a good correlation with clmnical results (Table 3 ). When the tumor was shown to be resistant in vitro, invariably no response was observed in vivo, thus suggesting a negative predictive value of 1.0.
Discussion
We have been able to culture a variety of tumors in a microtiter plate for drug evaluation. Morphological evaluation of stained cells confirms that the cells cultured are similar to the tumor cells of the original biopsy. For the cases of multiple myeloma and non-Hodgkin's lymphoma, the monoclonality of the cells after culture is confirmed by immunologic markers. In all eight cases studied, the cells have the same light-chain specificity of the cytoplasmic or surface immunoglobulins before and after culture. Routine staining of pleural and peritoneal effusion is occasionally inadequate for the recognition of malignant cells, especially when the effusion contains large numbers of reactive mesothelial cells.
One must determine a cell-dose curve for each tumor type, to find the optimal number for cell growth, because cells will enter exponential or plateau growth phase according to the initial number of cells (8) . Entry into the plateau phase of growth is most likely related to exhaustion of one or more growth-essential nutrients from the culture medium; such a condition should be avoided, to ensure that the lack of cell growth or the event of cell death is due to effects of the drug, rather than to the depletion of essential nutrients. Such a growth kinetic was clearly demonstrated by one of the cases of bladder carcinoma. For non-Hodgkin's lymphoma and multiple myeloma, we observed no plateau growth phase in the range of the initial cell numbers studied, which suggests that different tumor types may have different growth patterns in vitro. We chose a total culture time of five days for two reasons: First, the daily [3Hjthymidine uptake peaks around day four or five; after that, the DNA synthesis decreases, suggesting the beginning of plateau phase or cell death, owing to exhaustion of nutrient in the culture medium. Second, the drug effect, if any, usually manifests two to four days after treatment in vivo (9) (10) (11) .
To make predictions of in vivo response, we used the sensitivity of the tumor at the drug dose of 10% of that achievable in plasma because, on the one hand, the drug concentration entering or available to the tumor in vivo may be only a small fraction of the amount in plasma, but also because the softagar stem-cell assay system has shown that in vivo drug resistance is almost certain if a tumor colony is not inhibited at 5-10% of the drug concentration in plasma (12) .
Our definition of sensitive (less than 40% of control DNA synthesis) and resistant (greater than 60% of control DNA synthesis) tumors is still an operational one, and may change somewhat as more clinical correlations become available. The preliminary study showed a negative predictive value of 1.0; Roper and Drewinko (13) , using a human immunoglobulin-producing cell line (T1), also studied the effect of various drugs on DNA synthesis. In contrast to our results, they observed no drug dose-response curve. This discrepancy may be due to the differences in the cell types studied (established cell line vs cells from biopsied specimens), the culturing vehicle (Petri dish vs microtiter plate), or the composition of the culture medium. These factors will have profound effects on the cell-growth kinetics. In our experience, a drug dose curve is obtained only when the cultures remain in the growing phase during the experimental period, whereas the plateauphase cultures produce an irregular drug dose curve (unpublished data).
In accordance with our results, response to chemotherapy is also predicted with a thymidine-labeling index assay (14) . Briefly, colonies of cells growing on soft agar are pulsed with [3H]thymidine, then transferred onto a slide and processed for autoradiography.
The drug effect is expressed as the percentage of labeled cells enumerated by visual counting. The agreement in two assays is not surprising, in that both assays evaluate the effect of a drug by measuring DNA synthesis.
The tumor stem-cell assay system described by Hamberger and Salmon (15, 16) , used by a majority of investigators as a clinical predictor of response, basically involves growth of tumor colonies in a two-layer agar system. The determination of drug efficacy is based on a decrease in the number of colonies in treated cultures, and produces excellent correlations with clinical results (17) .
Therefore, we consider that there are basically two major methods for in vitro determination of tumor-cell drug sensitivity, each with its advantages and disadvantages. The advantages of the short assay we describe here are its short turnaround time (five or six days vs 21-28 days), the use of a cell harvestor and scintillation counting in the final step (thereby eliminating visual counting of colonies or labeled cells), and the fewer cells required (1 x i0 per well vs 5 X 10 per plate). Thus, determination of tumor sensitivity to a battery of drugs and production of a drug dose-response curve were usually possible for each tumor studied. The advantage of tumor stem-cell assays (15, 16) is that the colonies are identified morphologically as tumor colonies, whereas in our method the cell population must be monitored before and after culture by morphological or marker studies. The preliminary clinical correlation of this study is encouraging; however, further experience and improvements are necessary before clinical applications.
The technical improvements already underway include growth prevention of fibroblasts and mesothelial cells and the separation of nonviable from viable cells in solid-tumor specimens.
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